Dr. Neal Luther, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4 Hawthorne Dr, Bedford, NH 03110 Phone: 603-472-8888 Fax: 603-472-9090 |
Dr. Nigel Ross Jenkins, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4 Hawthorne Dr, Bedford, NH 03110 Phone: 603-472-8888 Fax: 603-472-9090 |
Kota Sadashiva Karanth, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4 Hawthorne Dr, Bedford, NH 03110 Phone: 603-472-8888 Fax: 603-472-9090 |
Dr. Theodore R Jacobs, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1 Hardy Rd # 220, Bedford, NH 03110 Phone: 603-472-4711 |
Paul P Wang, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4 Hawthorne Dr, Bedford, NH 03110 Phone: 603-472-8888 Fax: 603-472-9090 |
News Archive
Sen. Kyrsten Sinema formed a congressional caucus to raise "awareness of the benefits of personalized medicine" in February. Soon after that, employees of pharmaceutical companies donated $35,000 to her campaign committee.
Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.
Fibrocell Science, Inc. announced today that the Company has completed a private placement with certain accredited investors, pursuant to which the Company sold to the purchasers an aggregate of 41,409,458 shares of Company common stock at a purchase price of $0.55 per share.
In addiction, cues in the environment can form strong associations with the drug of abuse. A new study in Biological Psychiatry suggests that alterations in silent synapses, inactive connections between neurons, could be the neural mechanism underlying the formation of these drug-related memories.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.
› Verified 9 days ago